A randomized trial showed that empagliflozin (Jardiance), when added to standard care of patients with type 2 diabetes at high risk for cardiovascular events, reduced primary composite cardiovascular events and mortality from any cause. A total of 7020 patients were treated (median observation time, 3.1 years) with 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) occurred in 10.5% in the pooled empagliflozin group and in 12.1% in the placebo group (P=0.04 for superiority). There were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group), hospitalization for heart failure (2.7% and 4.1%, respectively), and death from any cause (5.7% and 8.3%, respectively) in patients receiving empagliflozin, and there was an increased rate of genital infection but no increase in other adverse events. This is the first study showing that a diabetes drug has a clear cardiovascular benefit. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2. Source: http://www.nejm.org/
一项随机试验表明，在心血管事件高风险的2型糖尿病患者的标准治疗中加入empagliflozin（Jardiance），减少了主要复合心血管事件和全因死亡率。共收治7020例患者（中位观察时间，3.1年），10毫克或25毫克empagliflozin，或安慰剂，每天一次。汇总的empagliflozin组主要复合指标（死于心血管病，非致死性心梗，或非致死性卒中）发生了10.5％，而安慰剂组为12.1％（P = 0.04的优势）。接受empagliflozin者心血管病死亡率（3.7％，而安慰剂组为5.9％），因心衰住院（分别为2.7％和4.1%），以及全因死亡率（分别为5.7％和8.3％）均显著降低，而生殖器感染的发生率增加，但其他不良事件并未增加。这是第一次有研究显示，糖尿病药物对心血管明显有益。 Empagliflozin是钠葡萄糖共转体2的抑制剂。来源：http://www.nejm.org/
This website uses cookies.